{"id":55078,"date":"2023-03-22T13:05:39","date_gmt":"2023-03-22T12:05:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/"},"modified":"2023-03-22T13:05:39","modified_gmt":"2023-03-22T12:05:39","slug":"cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/","title":{"rendered":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nTop-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer\u2019s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company.\n<\/li>\n<li>\nDr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors.\n<\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/SeriesB?src=hash\" target=\"_blank\" rel=\"noopener\">#SeriesB<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcognitotx.com%2F&amp;esheet=53363265&amp;newsitemid=20230322005004&amp;lan=en-US&amp;anchor=Cognito+Therapeutics&amp;index=1&amp;md5=89cb18e42f37ca4ccd748766b23f4c03\" rel=\"nofollow noopener\" shape=\"rect\">Cognito Therapeutics<\/a>, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. New investors Alzheimer\u2019s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company (Wilson Sonsini\u2019s venture arm) joined the round. The Series B funding brings the total amount raised since inception to $93 million.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/19\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.mp4\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740715\/5\/full_-_gardient_-_dark_text2x_4_4_1_5.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740715\/21\/full_-_gardient_-_dark_text2x_4_4_1_5.jpg\"><\/a><\/p>\n<p>\nIn addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder &amp; Managing Partner at FoundersX, will join Cognito\u2019s Board of Directors. Dr. Kuntz spent 17 years at Medtronic, where he initially led the company\u2019s neuromodulation business and then corporate technology and clinical research. Prior to Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute, now the Baim Institute, a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration.\n<\/p>\n<p>\nThe funding will advance Cognito\u2019s pivotal study of its non-invasive neuromodulation device, which delivers proprietary gamma frequency light and sound stimulation intended to treat Alzheimer\u2019s Disease. In a prior Phase 2 clinical trial, Cognito\u2019s device demonstrated a significant slowing in functional and cognitive decline in the treatment group, as well as a significant decline in brain atrophy over a six-month period. To further demonstrate the efficacy of the device, Cognito is currently enrolling patients in its pivotal clinical trial <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hopestudyforad.com%2F&amp;esheet=53363265&amp;newsitemid=20230322005004&amp;lan=en-US&amp;anchor=HOPE&amp;index=2&amp;md5=9d3dab55b3d70b923b664bbd058e3ddf\" rel=\"nofollow noopener\" shape=\"rect\">HOPE<\/a> for Alzheimer\u2019s Disease, across approximately 50 clinical centers in the United States with a target enrollment of 500 patients.\n<\/p>\n<p>\n\u201cAlzheimer\u2019s disease continues to be one of world&#8217;s largest public health problems, afflicting more than 55 million individuals globally. There is an urgent need to develop novel therapies that can safely delay the onset and progression of these neurodegenerative conditions,\u201d said Brent Vaughan, CEO, Cognito Therapeutics. \u201cThis funding will accelerate development of Cognito\u2019s home-based wearable device which has the potential to be a novel, safe, disease-modifying therapeutic approach to treat neurodegenerative diseases, starting with Alzheimer\u2019s. I am also delighted to welcome Dr. Kuntz to our team. His experience as the CMO and CSO of Medtronic, where he was instrumental in building their leading neuroscience medical device business will be extremely helpful to Cognito as we advance our technology for the millions of patients with neurological disorders.\u201d\n<\/p>\n<p>\n\u201cAbnormalities in the brain\u2019s electrophysiology represent exciting novel targets for the treatment of neurodegenerative diseases,\u201d said Dr. Kuntz, Board Member at Cognito Therapeutics. \u201cBy broadening the therapeutic target from specific proteins to the underlying neuronal pathophysiology, Cognito\u2019s proprietary approach has shown that it can fundamentally alter disease processes and potentially achieve disease modification unique from more traditional approaches. I look forward to working with the Cognito team to drive this technology forward for the benefit of patients worldwide.\u201d\n<\/p>\n<p>\n\u201cA non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimer\u2019s and Cognito is well-positioned to be a leader in this new paradigm,\u201d said Helen Liang, Founder &amp; Managing Partner, FoundersX Ventures. \u201cCognito is a pioneer at the unique intersection of biology and technology in using neuromodulation to potentially alter the trajectory of neurodegenerative diseases, and we\u2019re thrilled to support the advancement of this pivotal study in Alzheimer\u2019s.\u201d\n<\/p>\n<p>\nCognito\u2019s device is limited by United States law to investigational use only and is not available for sale. For more information on how to join the HOPE clinical study and enrollment, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hopestudyforad.com%2F&amp;esheet=53363265&amp;newsitemid=20230322005004&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.hopestudyforad.com%2F&amp;index=3&amp;md5=6df0fa70f19385cd3c28d5d1c155f00d\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.hopestudyforad.com\/<\/a>.\n<\/p>\n<p>\n<b>About Cognito Therapeutics<\/b>\n<\/p>\n<p>\nCognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company\u2019s lead therapy is currently in a pivotal study in Alzheimer\u2019s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cognitotx.com&amp;esheet=53363265&amp;newsitemid=20230322005004&amp;lan=en-US&amp;anchor=www.cognitotx.com&amp;index=4&amp;md5=8f73e79599c7c96ed2774e0659758546\" rel=\"nofollow noopener\" shape=\"rect\">www.cognitotx.com<\/a>. Follow us on Twitter at @cognitotx.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media<\/b><br \/>Kimberly Ha<br \/>\n<br \/>KKH Advisors<br \/>\n<br \/>917-291-5744<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;k&#x69;m&#x62;e&#x72;&#108;&#x79;&#46;&#x68;&#97;&#x40;&#107;&#x6b;&#104;&#x61;&#100;&#x76;&#105;s&#x6f;r&#x73;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">kimberly&#46;ha&#64;&#107;&#107;&#104;&#97;&#100;&#118;&#105;&#115;&#111;&#114;&#115;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer\u2019s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Dr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesB&#8212;Cognito Therapeutics, a neurotechnology company &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-55078","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer\u2019s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Dr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesB&#8212;Cognito Therapeutics, a neurotechnology company ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T12:05:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease\",\"datePublished\":\"2023-03-22T12:05:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/\"},\"wordCount\":753,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005004\\\/en\\\/1740717\\\/21\\\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/\",\"name\":\"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005004\\\/en\\\/1740717\\\/21\\\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\",\"datePublished\":\"2023-03-22T12:05:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005004\\\/en\\\/1740717\\\/21\\\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005004\\\/en\\\/1740717\\\/21\\\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend","og_description":"Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer\u2019s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Dr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesB&#8212;Cognito Therapeutics, a neurotechnology company ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-22T12:05:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease","datePublished":"2023-03-22T12:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/"},"wordCount":753,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/","url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/","name":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg","datePublished":"2023-03-22T12:05:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230322005004\/en\/1740717\/21\/cgn101_cognito_neuromodulationdevice_hd_230308_%281080p%29_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-raises-73m-series-b-to-advance-neurotechnology-platform-for-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55078"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55078\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}